Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021;50(3):402-404.
doi: 10.1159/000511392. Epub 2020 Oct 8.

Sudden Cardiac Death in Haemodialysis Patients under Hydroxychloroquine Treatment for COVID-19: A Report of Two Cases

Ahmet Murt  1 , Mevlut Tamer Dincer  2 , Cebrail Karaca  2
Affiliations
Case Reports

Sudden Cardiac Death in Haemodialysis Patients under Hydroxychloroquine Treatment for COVID-19: A Report of Two Cases

Ahmet Murt et al. Blood Purif. 2021.

Abstract

Hydroxychloroquine (HQ) has been used for the treatment of novel coronavirus disease (COVID-19) even though there is no clear evidence for its effectiveness yet. In contrary, HQ has major side effects like QTc prolongation and subsequent development of ventricular arrhythmias. Such side effects may possess additional risks on end-stage renal disease (ESRD) patients who have higher cardiovascular risks than general population. We herein present 2 cases of sudden cardiac death in 2 ESRD patients with COVID-19 for whom a treatment regimen including HQ was preferred. Both patients were clinically stable at the time of arrest. Death could not be attributed to worsening of the COVID-19 since the patients' clinical picture and laboratory values were improving. The cardiac events coincided with the end of routine haemodialysis sessions of both patients. Electrocardiography controls upon admission and on the 24 and 48 h of treatment showed normal QTc intervals. Potential risks contributing to sudden cardiac death during HQ treatment of ESRD patients are discussed.

Keywords: Coronavirus disease-19; End-stage renal disease; Haemodialysis; Hydroxychloroquine; Sudden death.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Comment in

References

    1. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with covid-19. N Engl J Med. 2020 Jun 18;385((25)):2411–8. - PMC - PubMed
    1. The cardiotoxicity of antimalarials WHO Malaria Policy Advisory Committee. Available from: https://www.who.int/malaria/mpac/mpac-mar2017-erg-cardiotoxicity-report-.... Accessed 2020 April 20.
    1. Garcia-Cremdes M, Solans BP, Hughes E, Ernest JP, Wallender E, Aweeka F, et al. Optimizing hydroxychloroquine dosing for patients with covid 19: an integrative modelling approach for effective drug repurposing. Clin Pharmacol Ther. 2020 Aug;108((2)):253–63. - PMC - PubMed
    1. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clin Infect Dis. 2020 Jul 28;71((15)):732–9. - PMC - PubMed
    1. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis. 2020 Apr 11;34:101663. - PMC - PubMed

Publication types

MeSH terms